Biosimilar to Eylea® (aflibercept)
Ophthalmology (neovascular AMD)
Phase 3Active (via Samsung Bioepis)
Key Facts
Indication
Ophthalmology (neovascular AMD)
Phase
Phase 3
Status
Active (via Samsung Bioepis)
Company
About Organon
Organon's mission is to improve the health of women throughout their lives by addressing critical gaps in reproductive health, contraception, fertility, and menopause. The company has achieved immediate global scale with a portfolio in over 140 markets, leveraging its heritage brands and deep commercial expertise. Its strategy focuses on maximizing the value of its established therapeutic portfolio, expanding access to biosimilars, and advancing a targeted pipeline in women's health to drive sustainable growth.
View full company profile